Top news story of the day:

Rona Therapeutics closes $33M Series A to advance RNA medicines

Rona Therapeutics said it closed a $33 million Series A financing round to build a delivery platform and scalable drug discovery engine to develop modular and programmable medicines.

The financing round was backed by Lilly Asia Ventures, CMB International, Platanus, Fontus Capital and Lanting Capital.

Founded in 2021, Rona Therapeutics aims to develop innovative and disruptive RNA medicines with a platform to enable therapeutics with more specific, stable and prolonged effects.

The company said the RNA medicines it is developing are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems.

For now, the company is building facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to develop RNA therapeutics.

By Elise Mak

What else in China:

Bohui Bio has completed a PreA+ round of financing of tens of millions of RMB, mainly for the research of small molecule inhibitors of intracellular immune checkpoints and building platforms for immune technology and small molecule coupling technology.

ArkBio announced that ziresovir met its primary endpoint in a Phase III trial for the treatment of hospitalized infants with RSV infection.

Carsgen announced the appointment of Dr. Raffaele Baffa as CMO to lead the global clinical development strategy and operations for the company's innovative pipeline product candidates. Dr. Baffa was previously CMO of Ziopharm.

By Sarina Yang